Edition:
United States

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

5.93CAD
10:50am EDT
Change (% chg)

$0.30 (+5.33%)
Prev Close
$5.63
Open
$5.70
Day's High
$6.00
Day's Low
$5.70
Volume
154,614
Avg. Vol
184,535
52-wk High
$6.00
52-wk Low
$1.70

Latest Key Developments (Source: Significant Developments)

Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territories
Monday, 6 Mar 2017 03:30am EST 

Theratechnologies Inc : Theratechnologies inc - agreement also includes upfront payment of US$3m payable through issuance of 906,077 common shares of Theratechnologies . Theratechnologies acquires commercial rights to Ibalizumab in the european union and four additional territories . Theratechnologies-Existing agreement between both companies has been amended to include additional territories and related new obligations . Theratechnologies inc -reached agreement with Taimed Biologics,for acquisition of commercial rights to Ibalizumab in European Union, Israel, Norway, Russia and Switzerland . Says under terms of agreement, Theratechnologies will assume regulatory responsibilities and associated costs . Theratechnologies inc - both parties have agreed to a transfer price of 52% for annual European sales up to us$50m .Says transfer price will increase to 57% on annual sales above us$50m threshold.  Full Article

Theratechnologies posts Q4 earnings per share C$0.00
Wednesday, 8 Feb 2017 07:30am EST 

Theratechnologies Inc : Theratechnologies announces financial results for fiscal year 2016 . Q4 revenue C$10.38 million versus I/B/E/S view c$9.6 million . Q4 earnings per share C$0.00 . Theratechnologies Inc - anticipate that FY net sales revenue will be in range of $40 million to $42 million .Theratechnologies -"we are now finalizing our plans for launch of ibalizumab in United States, which we believe will occur in 2017, if approved".  Full Article

Theratechnologies announces $16.5 mln bought deal financing
Monday, 14 Nov 2016 03:38pm EST 

Theratechnologies Inc : Theratechnologies announces $16.5 million bought deal financing .Underwriters to purchase, on a bought-deal basis, 5.3 million common shares of company at a price of $3.10 per common share.  Full Article

Theratechnologies Inc Q3 EPS C$0.01
Tuesday, 4 Oct 2016 07:00am EDT 

Theratechnologies Inc : Q3 earnings per share C$0.01 . Theratechnologies announces financial results for third quarter of 2016 . Q3 sales C$8.925 million .Theratechnologies Inc - Based upon results of our Q3, our guidance for year remains unchanged.  Full Article

Theratechnologies announces financial results for third quarter of 2016
Tuesday, 4 Oct 2016 07:00am EDT 

Theratechnologies Inc : Theratechnologies announces financial results for third quarter of 2016 . Q3 earnings per share c$0.01 . Qtrly revenue was $8.9 million compared to $9.2 million . Q3 sales c$8.925 million . For twelve months ending November 30, 2016, continue to expect that net sales of egrifta to be in range of $36 million to $37 million .Expectations for adjusted EBITDA in fiscal 2016 are still in range of $5 million to $6 million.  Full Article

Theratechnologies posts Q2 loss per share C$0.01
Tuesday, 5 Jul 2016 05:37pm EDT 

Theratechnologies Inc : Theratechnologies announces financial results for second quarter of 2016 . Q2 sales C$9.026 million .Q2 loss per share C$0.01.  Full Article

Theratechnologies says government of Quebec has refused to add Egrifta to list of reimbursed medications
Thursday, 9 Jun 2016 07:45am EDT 

Theratechnologies Inc : Theratechnologies inc says government of Quebec, province where Egrifta was discovered, has refused to add it to list of reimbursed medications . Government of Quebec, province where egrifta was discovered, has refused to add it to list of reimbursed medications .Inesss concluded that decrease of visceral adipose tissue in HIV patients does not constitute a therapeutic advantage.  Full Article

Theratechnologies says 82.5 pct of patients achieved the primary endpoint in late-stage trial of HIV drug
Tuesday, 24 May 2016 07:00am EDT 

Theratechnologies : Notified by partner of results for primary end point of phase iii trial with ibalizumab in patients with multi-drug resistant hiv-1 .Theratechnologies announces that 82.5% of patients achieved the primary endpoint in the phase iii ibalizumab trial.  Full Article

Theratechnologies Hires New Chief Financial Officer
Wednesday, 24 Feb 2016 04:13pm EST 

Theratechnologies:Says the hiring of Philippe Dubuc as Senior Vice President and Chief Financial Officer.  Full Article

Theratechnologies announces commercialization agreement for Tesamorelin in South Korea
Monday, 31 Aug 2015 04:21pm EDT 

Theratechnologies:Announces commercialization agreement for tesamorelin in South Korea.Says agreement has a 10-year term.Says BL&H intends to distribute egrifta in the territory through named patient sales programs.Bl&h will be responsible to conduct all regulatory activities required to obtain marketing approval for egrifta in South Korea.Says will manufacture and supply Egrifta(TM) to bl&h at a predetermined transfer price.  Full Article

More From Around the Web

BRIEF-Theratechnologies buys commercial rights to Ibalizumab in European Union and 4 additional territories

* Theratechnologies inc - agreement also includes upfront payment of US$3m payable through issuance of 906,077 common shares of Theratechnologies